Current and Novel Bronchodilators in Respiratory Disease

Domenico Spina

Disclosures

Curr Opin Pulm Med 

In This Article

Conclusion

β2-agonists and muscarinic antagonists are clinically effective and their combination has provided additional benefit in patients with COPD. However, both drug classes are not disease modifying and therefore treatment with an appropriate anti-inflammatory agent is necessary. Numerous bronchodilator targets are being evaluated and their potential as well tolerated and effective bronchodilators combined with anti-inflammatory activity could represent a new type of treatment for these respiratory diseases.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....